| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Learn more about BioRestorative Therapies Inc’s (BRTX) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
| Share Statistics | BRTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5.2 | $252.6 | 4% |
|
| Shares Out (Mil) | 17.7 | 52.3 | 29% |
|
| Institutional Ownership | 81.6% | 92.1% | 50% |
|
| Float (Mil) | 24.2 | 40.2 | 32% |
|
| Beta | 0.61 | 0.95 | 35% |
|
| Avg Daily Volume (000s) | 442 | 455 | 57% |
|
| Price Change (52-week) |
(86.2%) | 52.9% | 5% |
|
| Growth | BRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 32.0% | 13.6% | 91% |
|
| Net Income (5yr) | (4.7%) | (9.9%) | 34% |
|
| EPS (5yr) | 43.9% | 16.0% | 90 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (57.3%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.150) | ($0.660) | ($0.520) | |
| Month Ago EPS | ($0.150) | ($0.660) | ($0.520) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.150) | ($0.660) | ($0.520) | |
| Year/Year Chg | 23.0% | (58.3%) | (69.1%) | |
| Financials | BRTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $38 | 1% |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 28% |
|
| EPS (TTM) | ($0.975) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 18% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $5 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7 | $180 | 6% |
|
| Valuation | BRTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.71 | 2.56 | 45% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BRTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 92.1% | 63.8% | 94% |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (147.7%) | (49.8%) | 3% |
|
| ROE | (241.5%) | (55.5%) | 3% |
|
| Liabilities to Assets | 34.8% | 30.3% | 26% |
|
| F-Score | 3 | 3 | 19% |
|
BioRestorative Therapies, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
